ClinicalTrials.gg
CompletedNCT00776009Updated Jun 8, 2011Results posted

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

A Phase 4 interventional study of Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) and Placebo in Attention-Deficit/Hyperactivity Disorder (ADHD), sponsored by Novartis Pharmaceuticals. Completed at 8 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2011-06-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis — none open to participants now, none under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Novartis.

Enrollment
4th of 10
165 · median 146
Started
2008
the only one that year
Phase 4
2 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, this one is the 4th largest by enrollment, is the only one that started in 2008, is one of 2 in phase 4, and was the 8th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

None of the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis is open now. The open studies under Attention Deficit Disorder with Hyperactivity, anywhere →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis as a file.
02

Study summary

This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory classroom setting.

03

Conditions studied

  • Attention-Deficit/Hyperactivity Disorder (ADHD)

Keywords

  • ADHD, children, subjects, laboratory classroom
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 6-12 years, inclusive.
  • Subjects meeting the criteria for primary diagnosis of ADHD-Combined type, or predominantly hyperactive-impulsive subtype, as established by the K-SADS-PL (Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version). If a DSM-IV-defined ADHD diagnosis is difficult to establish due to possible co-morbidity, the subject will not be enrolled into the study.
  • Subjects should be on a stabilized total daily dose or nearest equivalent of 40-60 mg methylphenidate or 20-30 mg of d-methylphenidate for at least two weeks prior to Screening visit.

Exclusion criteria

Exclusion Criteria:

  • Subject or subject's guardian unable to understand or follow instructions necessary to participate in the study.
  • Diagnosed with or history of a tic disorder or Tourette's syndrome.
  • History of seizure disorder.
  • The presence of a known medical condition that would preclude the use of methylphenidate.
  • A history (within the past year) or presence of cardiovascular, cerebrovascular, renal, hepatic, gastrointestinal, pulmonary, immunological, hematological, endocrine, or neurological disease.
  • (Alanine Amino Transferase), AST (Aspartate Amino Transferase), GGT (Gamma glutamyl transferase) or serum creatinine greater then 2X the (Upper Limit of Normal) at Screening.
  • A history of psychiatric illness or substance use disorder (e.g., schizophrenia, bipolar disorder, autism, abuse or dependence, depression, severe Conduct Disorder or severe Oppositional defiant disorder)
  • Subjects who have participated in an trial within the past 4 weeks (28 days)
  • Subjects who are currently taking antidepressants or other psychotropic medication.
  • Subjects who have initiated psychotherapy during the three months prior to randomization.
  • Subjects with a positive urine drug screen.
  • Subjects who have a history of poor response or intolerance to methylphenidate or d-methylphenidate.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg

    Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.

    Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)

  • Active comparator
    Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg

    Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.

    Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)

  • Placebo comparator
    Placebo

    Two Capsules taken orally once a day for 7 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-dose

    SKAMP is a 13-item rating scale that measures classroom manifestations of ADHD consisting of 2 subscales (7 items for Attention and 6 items for Deportment) used to generate a score at Hours 10, 11 and 12 on Day 7 of Weeks 1, 2 and 3. The ratings were based on both frequency and quality of specific behaviors. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78. The reported measure is the difference from baseline of the 2 combined subscores averaged over Hours 10, 11 and 12. A negative score indicates improvement.

    Time frame: Pre-dose to 10, 11, and 12 hours post-dose

Secondary outcomes

  1. Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Attention Score at 10, 11, and 12 Hour (Averaged) Post-dose

    SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Attention subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42 for the Attention subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement.

    Time frame: Pre-dose to 10, 11, and 12 hours post-dose

  2. Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Deportment Score at 10, 11, and 12 Hour (Averaged) Post-dose

    SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Deportment subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36 for the Deportment subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement.

    Time frame: Pre-dose to 10, 11, and 12 hours post-dose

  3. Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Attempted Score at 10, 11, and 12 Hours (Averaged) Post-dose

    Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement.

    Time frame: Pre-dose to 10, 11, and 12 hours post-dose

  4. Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Correctly Answered Score at 10, 11, and 12 Hours (Averaged) Post-dose

    Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement.

    Time frame: Pre-dose to 10, 11, and 12 hours post-dose

07

Results

Posted Mar 16, 2011

Participant flow

Period 1: First Intervention
Participant flow — Period 1: First Intervention
MilestoneFocalin XR 20 mg First, Then Focalin XR 30 mg, Then PlaceboFocalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mgFocalin XR 30 mg First, Then Focalin XR 20 mg, Then PlaceboPlacebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mgFocalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mgPlacebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mg
Started262829272827
Completed262728272627
Not completed011020
Withdrew: Withdrawal by subject001010
Withdrew: Protocol violation010010
Period 2: Second Intervention
Participant flow — Period 2: Second Intervention
MilestoneFocalin XR 20 mg First, Then Focalin XR 30 mg, Then PlaceboFocalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mgFocalin XR 30 mg First, Then Focalin XR 20 mg, Then PlaceboPlacebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mgFocalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mgPlacebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mg
Started262728272627
Completed252727272626
Not completed101001
Withdrew: Withdrawal by subject000001
Withdrew: Protocol violation101000
Period 3: Third Intervention
Participant flow — Period 3: Third Intervention
MilestoneFocalin XR 20 mg First, Then Focalin XR 30 mg, Then PlaceboFocalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mgFocalin XR 30 mg First, Then Focalin XR 20 mg, Then PlaceboPlacebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mgFocalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mgPlacebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mg
Started252727272626
Completed242727272626
Not completed100000
Withdrew: Withdrawal by subject100000

Outcome measures

PrimaryChange From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-dose

SKAMP is a 13-item rating scale that measures classroom manifestations of ADHD consisting of 2 subscales (7 items for Attention and 6 items for Deportment) used to generate a score at Hours 10, 11 and 12 on Day 7 of Weeks 1, 2 and 3. The ratings were based on both frequency and quality of specific behaviors. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78. The reported measure is the difference from baseline of the 2 combined subscores averaged over Hours 10, 11 and 12. A negative score indicates improvement.

Time frame:
Pre-dose to 10, 11, and 12 hours post-dose
Reported as:
Least squares mean · Scores on a scale
Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-dose
Scores on a scaleDex-Methylphenidate Hydrochloride (Focalin XR) 20 mgDex-Methylphenidate Hydrochloride (Focalin XR) 30 mgPlacebo
Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-dose-2.02 ± 0.717-4.47 ± 0.7244.50 ± .723
SecondaryChange From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Attention Score at 10, 11, and 12 Hour (Averaged) Post-dose

SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Attention subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42 for the Attention subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement.

Time frame:
Pre-dose to 10, 11, and 12 hours post-dose
Reported as:
Least squares mean · Scores on a scale
Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Attention Score at 10, 11, and 12 Hour (Averaged) Post-dose
Scores on a scaleDex-Methylphenidate Hydrochloride (Focalin XR) 20 mgDex-Methylphenidate Hydrochloride (Focalin XR) 30 mgPlacebo
Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Attention Score at 10, 11, and 12 Hour (Averaged) Post-dose-1.33 ± 0.397-2.62 ± 0.4000.94 ± 0.405
SecondaryChange From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Deportment Score at 10, 11, and 12 Hour (Averaged) Post-dose

SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Deportment subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36 for the Deportment subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement.

Time frame:
Pre-dose to 10, 11, and 12 hours post-dose
Reported as:
Least squares mean · Scores on a scale
Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Deportment Score at 10, 11, and 12 Hour (Averaged) Post-dose
Scores on a scaleDex-Methylphenidate Hydrochloride (Focalin XR) 20 mgDex-Methylphenidate Hydrochloride (Focalin XR) 30 mgPlacebo
Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Deportment Score at 10, 11, and 12 Hour (Averaged) Post-dose-0.39 ± 0.423-1.49 ± 0.4262.95 ± 0.424
SecondaryChange From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Attempted Score at 10, 11, and 12 Hours (Averaged) Post-dose

Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement.

Time frame:
Pre-dose to 10, 11, and 12 hours post-dose
Reported as:
Least squares mean · Number attempted
Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Attempted Score at 10, 11, and 12 Hours (Averaged) Post-dose
Number attemptedDex-Methylphenidate Hydrochloride (Focalin XR) 20 mgDex-Methylphenidate Hydrochloride (Focalin XR) 30 mgPlacebo
Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Attempted Score at 10, 11, and 12 Hours (Averaged) Post-dose18.76 ± 3.06528.03 ± 3.078-0.23 ± 3.073
SecondaryChange From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Correctly Answered Score at 10, 11, and 12 Hours (Averaged) Post-dose

Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement.

Time frame:
Pre-dose to 10, 11, and 12 hours post-dose
Reported as:
Least squares mean · Number correct
Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Correctly Answered Score at 10, 11, and 12 Hours (Averaged) Post-dose
Number correctDex-Methylphenidate Hydrochloride (Focalin XR) 20 mgDex-Methylphenidate Hydrochloride (Focalin XR) 30 mgPlacebo
Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Correctly Answered Score at 10, 11, and 12 Hours (Averaged) Post-dose18.45 ± 2.46128.02 ± 2.480-4.30 ± 2.474

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dex-Methylphenidate Hydrochloride (Focalin XR) 30 mg—0/165 (0%)10/165 (6.1%)
Dex-Methylphenidate Hydrochloride (Focalin XR) 20 mg—1/165 (0.6%)8/165 (4.8%)
Placebo—0/165 (0%)0/165 (0%)
Most frequent serious events
Most frequent serious events
EventDex-Methylphenidate Hydrochloride (Focalin XR) 30 mgDex-Methylphenidate Hydrochloride (Focalin XR) 20 mgPlacebo
Peritonsillar abscessInfections and infestations0/1651/1650/165
Most frequent other events
Most frequent other events
EventDex-Methylphenidate Hydrochloride (Focalin XR) 30 mgDex-Methylphenidate Hydrochloride (Focalin XR) 20 mgPlacebo
Decreased appetiteMetabolism and nutrition disorders10/1658/1650/165

Baseline characteristics

Age Continuous
Age Continuous(Years)Focalin XR 20 mg First, Then Focalin XR 30 mg, Then PlaceboFocalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mgFocalin XR 30 mg First, Then Focalin XR 20 mg, Then PlaceboPlacebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mgFocalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mgPlacebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mgTotal
Mean9.3 ± 1.79.4 ± 1.710.0 ± 1.89.4 ± 2.09.5 ± 1.89.6 ± 2.09.6 ± 1.8
Sex: Female, Male
Sex: Female, Male(Participants)Focalin XR 20 mg First, Then Focalin XR 30 mg, Then PlaceboFocalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mgFocalin XR 30 mg First, Then Focalin XR 20 mg, Then PlaceboPlacebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mgFocalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mgPlacebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mgTotal
Female9161010121471
Male17121917161394
Region of Enrollment
Region of Enrollment(participants)Focalin XR 20 mg First, Then Focalin XR 30 mg, Then PlaceboFocalin XR 30 mg First, Then Placebo, Then Focalin XR 20 mgFocalin XR 30 mg First, Then Focalin XR 20 mg, Then PlaceboPlacebo First, Then Focalin XR 20 mg, Then Focalin XR 30 mgFocalin XR 20 mg First, Then Placebo, Then Focalin XR 30 mgPlacebo First, Then Focalin XR 30 mg, Then Focalin XR 20 mgTotal
United States262829272827165
08

Study locations

8 sites
  • Clinical Study Center, LLC
    Little Rock, Arkansas 72205, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34208, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
  • Center for Psychiatry and Behavioral Medicine, Inc.
    Las Vegas, Nevada 89128, United States
  • Bayou City Research
    Houston, Texas 77007, United States
  • Claghorn-Lesem Research Clinic
    Houston, Texas 77008, United States
  • Behavioral Neurology
    Lubbock, Texas 79423, United States
09

References and documents

Publications

  • Brams M, Turnbow J, Pestreich L, Giblin J, Childress A, McCague K, Muniz R. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control. J Clin Psychopharmacol. 2012 Oct;32(5):637-44. doi: 10.1097/JCP.0b013e3182677825. Erratum In: J Clin Psychopharmacol. 2012 Dec;32(6):766. PubMed 22926597 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2008
First posted
Oct 20, 2008
Start
Oct 2008
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Mar 16, 2011
Last update
Jun 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00776009
First posted
Oct 20, 2008
Start date
Oct 2008
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Mar 16, 2011
Last update
Jun 8, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmethylphenidate

Start the discussion